Language Minimizing Adverse Events; HPV and Thyroid Cancer; Ultrasound Bras

Using language that minimizes adverse events in studies presented at oncology conferences could compromise patient care. (Journal of Cancer Policy)

While care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx is shifting toward community cancer centers, patients treated in this setting may have poorer outcomes. (Johns Hopkins University School of Medicine, Journal of the National Cancer Institute).

Meanwhile, a Taiwanese study found that patients with prior HPV infection were twice as likely to develop thyroid cancer compared with patients without the infection. (Scientific Reports)

A California man with acute myeloid leukemia has found a suitable bone-marrow donor in the Philippines — but the donor’s request for a visa has been denied. (ABC7 Los Angeles)

Visa issues may also prevent an Ohio woman with stage IV colorectal cancer from seeing her father before she dies. (WCPO Cincinnati)

Could an ultrasound bra detect breast cancer sooner? (Wired)

Researchers found that contact with cigarette smoke not only affects human health, but was also associated with cancer in dogs. (Purdue University, The Veterinary Journal)

The American Cancer Society has awarded the 2024 Medal of Honor — the society’s most prestigious award — to Pasi A. Jänne, MD, PhD, of the Dana-Farber Cancer Institute in Boston.

Innate Pharma announced that the FDA has lifted a partial hold that was placed on the lacutamab clinical program following a patient death in the TELLOMAK study, an ongoing phase II trial of lacutamab in cutaneous T-cell lymphoma.

Researchers have developed a chimeric antigen receptor T-cell therapy targeting T-cell lymphoma that demonstrated early signals of anti-tumor efficacy and safety. (Baylor College of Medicine, Blood)

The FDA granted Fast Track designation for rinatabart sesutecan, a folate receptor alpha (FRα) targeted antibody-drug conjugate, for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer, ProFoundBio announced.